Global Nucleic Acid Therapeutics CDMO Market to grow at CAGR of 8.14% through 2029
Increasing
healthcare infrastructure and a supportive regulatory environment are the major
drivers for the Global Nucleic Acid Therapeutics CDMO Market in the forecast period 2025-2029
According
to TechSci Research report, “Global Nucleic Acid Therapeutics CDMO Market
Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2019-2029”, Global Nucleic Acid
Therapeutics CDMO Market was valued at USD 11.48 billion in 2023 and is
anticipated to witness an impressive growth in the forecast period with a CAGR
of 8.14% through 2029.
Collaborations and partnerships among leading companies have been instrumental in merging individual expertise and strengthening market positions. Technological advancements in Nucleic Acid Therapeutics CDMO (Contract Development and Manufacturing Organization) have significantly advanced the development and production of nucleic acid-based therapies. These advancements have notably enhanced the efficiency, safety, and versatility of nucleic acid therapeutic development. The emergence of mRNA vaccine platforms, exemplified by COVID-19 vaccines from Pfizer-BioNTech and Moderna, represents a groundbreaking advancement. These platforms demonstrate the ability to swiftly develop and manufacture vaccines for emerging infectious diseases.
Innovations in nucleic acid therapeutic delivery have been pivotal. Lipid nanoparticles, lipid-based carriers, and other non-viral delivery systems have enhanced the safety and efficiency of RNA and DNA delivery to target cells. Additionally, CRISPR-Cas9 and other gene editing techniques have revolutionized the precision in gene modification, with broad applications in treating genetic disorders, cancer, and other diseases. RNAi-based therapies, including small interfering RNA (siRNA) and short hairpin RNA (shRNA), have become more efficient and specific. These technologies are utilized to silence or "turn off" specific disease-related genes.
Browse
over XX market data Figures and spread through XX
Pages and an in-depth TOC on " Global Nucleic Acid Therapeutics CDMO Market”
The adoption of continuous manufacturing techniques for RNA offers several significant advantages, including enhanced efficiency, increased productivity, improved quality control, cost-effectiveness, and scalability. Exothera is launching a dedicated business unit called Exothera Nucleic Acids, with a focus on accelerating the development and production of RNA vaccines and therapeutics. Through the integration of Exothera's extensive development and manufacturing experience with Quantoom's innovative continuous biomanufacturing platform, this partnership aims to streamline the RNA vaccine development process, expediting both clinical trials and commercialization. Pricing and reimbursement pose significant challenges in the Global Nucleic Acid Therapeutics CDMO (Contract Development and Manufacturing Organization) Market. These challenges are particularly complex due to the unique nature of nucleic acid therapeutics, which encompass gene therapies, RNA-based drugs, and personalized treatments.
The development of nucleic acid therapeutics, including gene therapies, often entails substantial research and development costs incurred during pre-clinical studies, clinical trials, and regulatory submissions. High development costs can present challenges in pricing these therapies at levels that ensure affordability and accessibility. Manufacturing nucleic acid therapeutics can be technically intricate and costly. Balancing reasonable production costs with quality standards poses a challenge. Moreover, many nucleic acid therapeutics are personalized or tailored to individual patients, making pricing and reimbursement more complex. Each treatment may necessitate specific pricing models. Rare diseases, often targeted by nucleic acid therapeutics, have small patient populations. This presents pricing challenges, as the limited patient base may not support conventional pricing models.
Global Nucleic Acid Therapeutics CDMO Market is
segmented based on Type, Service, Application, and by region.
Based
on the application, The Oncology segment exerts a dominant presence in the Global Nucleic Acid Therapeutics CDMO (Contract Development and Manufacturing Organization) Market. Oncology represents a significant area of focus for nucleic acid therapeutics development. Nucleic acid-based therapies, including gene therapies, RNA interference (RNAi) therapeutics, and antisense oligonucleotides, offer promising avenues for treating various types of cancer. These therapies can target specific genetic mutations or pathways involved in cancer growth and progression, presenting a highly targeted approach to treatment. The complexity and heterogeneity of cancer make it an ideal candidate for personalized medicine approaches, which are facilitated by nucleic acid therapeutics. By targeting specific genetic alterations present in individual patients' tumors, nucleic acid-based therapies can be tailored to the unique molecular profile of each patient's cancer. This personalized approach holds great promise for improving treatment outcomes and minimizing adverse effects. The growing understanding of the molecular mechanisms underlying cancer development and progression has fueled the rapid advancement of nucleic acid therapeutics in oncology. Advances in genomic sequencing technologies have enabled the identification of novel cancer-associated genes and pathways, providing a wealth of targets for nucleic acid-based interventions.
Also, the Oncology segment benefits from a robust pipeline of nucleic acid therapeutics candidates in various stages of development. Numerous companies and research institutions are actively engaged in developing nucleic acid-based therapies for the treatment of various cancers, ranging from solid tumors to hematological malignancies. The increasing prevalence of cancer worldwide further drives the demand for innovative treatment modalities such as nucleic acid therapeutics. With cancer incidence on the rise globally, there is a growing need for effective and targeted therapies that can improve patient outcomes and survival rates. The Oncology segment dominates the Global Nucleic Acid Therapeutics CDMO Market due to the significant opportunities presented by nucleic acid-based therapies in addressing the complex and heterogeneous nature of cancer, the growing emphasis on personalized medicine approaches, advances in cancer genomics, a robust pipeline of therapeutics candidates, and the increasing prevalence of cancer worldwide.
North America, especially the United States, boasts a thriving biotechnology and pharmaceutical industry, hosting numerous major biopharmaceutical companies and innovative startups. These firms often require CDMO (Contract Development and Manufacturing Organization) services for nucleic acid therapeutics development and production. With a rich history of investment in research and development, North America serves as a focal point for innovation in the life sciences sector. This culture of innovation has spurred the creation of cutting-edge nucleic acid therapeutics, thereby fueling demand for CDMO services. The United States benefits from well-established regulatory agencies such as the U.S. Food and Drug Administration (FDA), which have played a pivotal role in facilitating the development and approval of nucleic acid therapeutics. The regulatory framework instills confidence among companies seeking to invest in this sector. Also, the region provides access to substantial financial resources, including venture capital and public funding. This financial backing empowers both biotech startups and established companies to allocate resources towards nucleic acid therapeutic development, including outsourcing to CDMOs.
Some of the major companies
operating in the Global Nucleic Acid
Therapeutics CDMO Market include:
- Catalent Inc.
- Thermo Fisher Scientific Inc.
- Lonza Group Ltd.
- FUJIFILM Diosynth Biotechnologies
U.S.A., Inc.
- Charles River Laboratories
International, Inc.
- Eurofins Genomics
- Sirion Biotech GmbH
- Oxford Biomedica Plc.
- Danaher Corp
Download Free Sample Report
Customers can also request
for 10% free customization on this report
“The market for Contract Development and
Manufacturing Organizations (CDMOs) specializing in nucleic acid therapeutics
has experienced steady growth. Nucleic acid therapies, such as mRNA vaccines
and gene therapies, have garnered significant attention for their potential in
treating a range of diseases, including genetic disorders, cancers, and
infectious diseases. Looking ahead, the nucleic acid therapeutics CDMO market
is poised for further expansion and innovation. With increasing demand for
RNA-based therapies, CDMOs are pivotal in delivering specialized manufacturing
and development solutions to pharmaceutical companies and biotechs.," said
Mr. Karan Chechi, Research Director, TechSci Research, a research-based
Global management consulting firm.
“Nucleic Acid Therapeutics CDMO Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Gene Therapy, RNA-based Therapies), By Service (Process Development & Optimization, Manufacturing Services, Analytical and Quality Control Services, others), by Application (Oncology, Genetic Disorders, Infectious Diseases, others), by region, and Competition, 2019-2029F” has evaluated the future growth potential of Global
Nucleic Acid Therapeutics CDMO Market and
provides statistics & information on market size, structure, and future
market growth. The report intends to provide innovative market intelligence and
help decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Nucleic Acid Therapeutics CDMO Market.
Contact
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +13322586602
Email: [email protected]
Website: www.techsciresearch.com